Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Prostatic Neoplasms 3Leukemia 3Hematologic Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, B-Cell 2Lung Neoplasms 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nose Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

sacituzumab govitecan 1bintrafusp alfa protein, human 1avelumab 1Tomography, X-Ray Computed 1Nivolumab 1Ipilimumab 1Electrocardiography 1Echocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Solid Tumors × Electrocardiography × Clear all
NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
31 enrolled 20 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡